Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nivolumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData,...
Nivolumab by Ono Pharmaceutical for Mantle Cell Lymphoma: Likelihood of Approval
Nivolumab is under clinical development by Ono Pharmaceutical and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for T-Cell Lymphomas: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pediatric Diffuse Intrinsic Pontine Glioma. According...
Nivolumab by Bristol-Myers Squibb for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....
Nivolumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Nivolumab by Bristol-Myers Squibb for Skin Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Skin Cancer. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Nasopharyngeal Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Nivolumab by Bristol-Myers Squibb for Kaposi Sarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Primary Mediastinal B-Cell Lymphoma. According to...
Nivolumab by Bristol-Myers Squibb for Malignant Fibrous Histiocytoma of Soft Tissue: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Malignant Fibrous Histiocytoma of Soft Tissue....
Nivolumab by Bristol-Myers Squibb for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Nivolumab by Bristol-Myers Squibb for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...
Nivolumab by Bristol-Myers Squibb for Neuroblastoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...
Nivolumab by Bristol-Myers Squibb for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to...